DoD Signs Agreement with BioFire Defense to Increase COVID-19 Test Kit Production

DoD Signs Agreement with BioFire Defense to Increase COVID-19 Test Kit Production
COVID-19 Test Kits

The Department of Defense (DoD) has entered into a $3.1 million agreement with bioMerieux's BioFire Defense subsidiary to increase manufacturing capacity for COVID-19 test kits.

The company will use the investment to install two new production lines into its facility in Salt Lake City to expand test kit production in September, DoD said Monday.

BioFire's test kits are built to work with the company's FilmArray panel, an instrument designed to help users identify pathogens related to an infectious disease.

The agreement is a part of the Joint Acquisition Task Force's efforts to ensure the availability of medical resources via the Defense Production Act Title III program.

Check Also

DoD

DoD Uses Commercial Tech for Early Coronavirus Detection

The Defense Threat Reduction Agency (DTRA) partnered with the Defense Innovation Unit to use a commercial, wearable infection warning device for COVID-19 spread reduction, DoD News reported Tuesday. The device, named Rapid Analysis of Threat Exposure, is designed to alert about the virus' presence in the wearer before he or she exhibits symptoms.